Spectral Al®

Predictive Wound Healing

AI + Multispectral Imaging = Faster, More Accurate Treatment Decisions in Healthcare Nasdaq: MDAI | August 2024 E Deep View SnapShot™

©2024 Spectral A



Al-Driven wound assessment technology designed to deliver value across the healthcare continuum	17.6 Million shares outstanding August 9, 2024
Supported by \$250M+ non-dilutive government funding	2023E \$18M 2024E \$28M Financial position at 6/30/2024 Cash \$6.9M
Large and growing addressable markets	Intellectual property portfolio 26 issued 38 pending
Clear regulatory pathway	Headquarters Dallas, TX
Limited competition	Founded
Strong competitive barriers to entry	NASDAQ MDAI

1

ॐ

Recent Accomplishments

Received Burn-Al for UKCA classification	Secured \$10.0 Million Committed Equity Facility	Strengthened Board and Management Team	Joined Russell Microcap Index
Completed 100% Pediatric Burn Center Enrollment	PolyNovo MOU to support Australian Special Access Scheme (SAS)	Additional Patent Grants for Total Number of 26	\$13.8 Million in Revenue for H1 2024

ॐ

Revolutionizing Wound Care

- Our DeepView[™] system enables healthcare providers to make more informed treatment choices.
- In a matter of seconds during the initial patient visit, DeepView[™] **predicts**¹ **if the wound will heal or not**, with remarkable accuracy.

Delivering on Commitments

11-year track record

2013-2024

of meeting milestones validated by \$250M non-dilutive government funding

- Proof of concept
- Clinical validation
- Product validation
- Product prototyping
- Pre-sub regulatory alignment



Prioritizing growth opportunities in profitable markets, positioning ourselves for nearterm commercial success.




DeepView[™] is a single platform supporting multiple indications.



Extensive portfolio of patents, trade secrets and "truthed" images are a significant barrier to competition.

OUR TECHNOLOGY



One Imaging Platform, **Multiple Indications**



INDICATIONS





2026 🔮 2027

Potential Clinical Indications

Wound Bed Preparedness Amputation Digital Guided Therapy

Critical Limb Ischemia

DeepView SnapShot[®] M | Handheld

Military anticipate selling




Total grant awarded \$7.1M for miniaturization of technology

Miniaturized Mobile Home Healthcare



*

Targeting Multiple Care Centers



U.S. AND GLOBAL IP

Intellectual property formidable barrier to entry

Active patent application families protecting our current and anticipated future business

- Burn/Wound classification on MSI and PPG
- Tissue classification on MSI and PPG
- Amputation site analysis on MSI, machine learning and healthcare matrix
- DFU healing potential prediction and wound assessment on MSI, machine learning and healthcare matrix
- High-precision, multi-aperture, MSI snapshot imaging

- Wound assessment on MSI, optical, biomarkers, and machine learning
- Burn/Histology assessment on MSI and machine learning
- High-precision single aperture snapshot imaging with multiplexed illumination
- Topological characterization and assessment of tissue including wounds, using MSI and machine learning

U.S. & International Patents issued and allowed Pending U.S. & International patent applications

7

X

38

ACTIVE MANAGEMENT OF IP PORTFOLIO

- Useful life on key patent protection on core concepts exceeds 14 years
- Proprietary physician review image library for Burn and DFU
- Engage leading experts to constantly evaluate IP strategy and execution

©2024 Spectral AI



Solution ≥ Deep View

A PROBLEM

No existing diagnostic tool for burn leading to uninformed decisions. Burn evaluation relies on visual examination and subjective judgement, often leading to inaccuracies.

CURRENT SOLUTION

Wait and See as Tissue Changes to Know Severity

Standard of care is to wait up to 7 days to determine need for surgery.⁶


OUR SOLUTION

Burn professional healing accuracy prediction is 75% (specialist).

ANTICIPATED BENEFITS


- Reduces time to surgery⁸
- Avoids unnecessary surgeries⁹
- Reduced transfers that can be treated locally
- Uniformed standardized TBSA measurements

US Commercialization Sequence




MARKET ACCESS

Key Steps to Successful Global Market Access



©2024 Spectral A

Clinical evidence quantifies health system benefits



- Standardized total body surface area (TBSA) measurement
- **41% reduction** in unnecessary transfer¹³
- Unnecessary surgery admission costs reduction per patient of \$58,315¹⁴ ¹⁵
- **3+ day reduction time to surgery** for burns¹⁴ ¹⁶ (>30% reduction in LOS)

Initial penetration in United Kingdom market generates early proof of clinical benefits

BARDA SUPPORT OVER THE YEARS

Management's track record through years of BARDA engagement validates and increases probability of success for DeepView[™] across clinical indications (Burn and DFU/Other) and geography (U.S., UK, EMEA).



Procurement Contract Options

Commercialization

Procurement





TOTAL


CURRENTLY 16 CLINICAL RESEARCH SITES SPREAD ACROSS THE US ENROLLING TO COMPLETE PIVOTAL TRIAL

Clinical Trial Update

Why are they unique?	Why are they unique?
25 burn centers with 250 burn surgeons nationwide	5,000 Emergency Departments with no burn specialized
85%+ Completed	15%+ Completed
Anticipated Enrollment Completion: September 2024	Anticipated Enrollment Completion: April 2025
Burn Center	Emergency Departments
Total Enrollment Goal: 160	Total Enrollment Goal: 160



Planned near-term **product deployments**





While Spectral AI believes it will obtain regulatory clearance on its MSI and AI Software for its DeepView Gen 3 device, there can be no assurance that it will receive such regulatory clearance or that it will receive such clearance in its anticipated timelines.

REVENUE OPPORTUNITY

Includes AI annuity and one-time device sales

Research and Development

- BARDA PBS Contract includes \$55M R&D revenue spread across 4Q23 1Q26
- Modest additional R&D revenue from MTEC in 2024
- BARDA PBS Contract anticipates \$95M revenue beginning no later than 2Q26

UK DeepView Commercialization

- Anticipated initial sales are a three-year bundled total, including a leased monthly payment
- Multiple care settings, such as Trauma and A&E, being targeted

U.S. DeepView Commercialization


- Initial sales will also be focused on developing real-world evidence (RWE)
- Ongoing pricing per click and device sales being evaluated
- o Annuity payment with and without device one time sale
- o Reimbursement being developed

Additional Revenue Sources

- Global expansion following US De Novo Clearance
- Annuity payment from AI licensing fees



Spectral IP Subsidiary




SYSTEMWIDE BENEFITS

Improving health and cost outcomes for all



©2024 Spectral A

Investment Summary



02024 Spectral A





 \checkmark



Summary balance sheets

\$ thousands	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024
Cash	10,316	8,166	7,348	4,790	10,157	6,877
Accounts receivable, net	1,884	1,520	1,312	2,346	1,828	2,295
Other Current Assets	1,128	2,155	2,696	2,766	2,899	2,489
Total Current Assets	13,328	11,841	11,356	9,902	14,884	11,661
Non-current Assets	854	1,157	975	790	599	2,236
Total Assets	14,182	12,998	12,331	10,692	15,483	13,897
Accounts Payable	2,018	2,654	3,275	2,683	3,306	2,403
Accrued Expenses	2,361	2,394	3,983	4,300	3,818	2,733
Other Current Liabilities	975	1,476	3,389	5,418	10,387	10,990
Total Current Liabilities	5,354	6,524	10,647	12,401	17,511	16,126
Non-current Liabilities	142	452	228	-	-	2,036
Total Liabilities	5,496	6,976	10,875	12,401	17,511	18,162
Stockholders' Equity (Deficit)	8,686	6,022	1,456	(1,709)	(2,028)	(4,265)
Total Liabilities and Stockholders' Equity	14,182	12,998	12,331	10,692	15,483	13,897



Summary income statements

\$ thousands (except per share data)	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024
Research and Development Revenue	5,078	4,251	3,440	5,287	6,326	7,478
Cost of Revenue	(2,897)	(2,460)	(1,968)	(2,851)	(3,381)	(4,164)
Gross Profit	2,181	1,791	1,472	2,436	2,945	3,314
Operating Expenses	5,079	4,782	5,638	5,365	5,088	5,756
Operating Income (Loss)	(2,898)	(2,991)	(4,166)	(2,929)	(2,143)	(2,442)
Transaction Costs	-	-	(7,604)	-	(848)	-
Other Income (Expense)	(665)	(39)	1,087	(638)	(192)	(353)
Loss Before Income Taxes	(3,563)	(3,030)	(10,683)	(3,567)	(3,183)	(2,795)
Income Tax (Provision) Benefit	(46)	(40)	54	21	(22)	(69)
Net Loss	(3,609)	(3,070)	(10,629)	(3,546)	(3,205)	(2,864)
Net Loss per Share	(0.27)	(0.23)	(0.77)	(0.22)	(0.19)	(0.16)
Number of shares o/s	13,190,635	13,210,320	13,822,990	16,097,399	16,560,298	17,598,357

21



Summary cash flow statements

\$ thousand	s Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024
Net Loss	(3,609)	(3,070)	(10,629)	(3,546)	(3,205)	(2,864)
Stock-based Compensation	300	396	279	268	283	402
Depreciation	2	3	2	2	3	2
Amortization of Right-of-Use Assets	173	177	180	183	188	132
Issuance of Shares for Transaction Costs	-	-	1,800	2,550	-	-
Commitment to issue shares for transaction cost	-	-	2,550	(2,550)	-	-
Change in Fair Value of warrant liabilities	(16)	81	(1,069)	669	(20)	(348)
Change in fair value of notes payable	-	-	-	-	(66)	167
Cost from issuance common stock	-	-	-	-	147	225
Changes in Assets	500	468	(381)	(1,032)	102	(57)
Changes in Liabilities	(1,105)	173	1,930	1,081	(112)	(3,021)
Net Cash Used in Operating Activities	(3,755)	(1,772)	(5,338)	(2,375)	(2,680)	(5,362)
Net Cash Used in Investing Activities	-	-	-	-	-	-
Proceeds from Issuance of Common Stock	-	-	3,351	-	2,667	
Cash Received in Business Combination	-	-	660	-	-	-
Payments for Notes Payable	(104)	(71)	(113)	288	(218)	(2,518)
Proceeds from Notes payable – related party	-	-	-	-	1,000	
Proceeds from Notes payable	-	-	-	(483)	4,600	4,600
Payments of deferred offering costs	-	(306)	306	-	-	-
Stock Option Exercises	-	-	316		-	-
Net Cash Provided By (Used In) Financing Activities	(104)	(377)	4,520	(195)	8,049	2,082
Effect of Exchange Rate Changes on Cash	1	(1)	-	12	(2)	
Net Increase (Decrease) in Cash	(3,858)	(2,150)	(818)	(2,558)	5,367	(3,280)
Beginning Cash Balance	14,174	10,316	8,166	7,348	4,790	10,157
Ending Cash Balance	10,316	8,166	7,348	4,790	10,157	6,877



Non-GAAP reconciliation

\$ thousan	ds Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024
Net Loss	(3,609)	(3,070)	(10,629)	(3,546)	(3,205)	(2,864)
Income Tax Provision (Benefit)	46	40	(54)	(21)	22	69
Net Interest (Income) Expense	(45)	(41)	(42)	(44)	(14)	6
EBIT	(3,608)	(3,071)	(10,725)	(3,611)	(3,197)	(2,789)
Depreciation Expense	2	3	2	2	3	2
EBITDA	(3,606)	(3,068)	(10,723)	(3,609)	(3,194)	(2,787)
Stock-based Compensation	300	396	279	268	283	402
Borrowing related costs	-	-	-	-	276	699
Change in Fair Value of Warrant Liability	(16)	81	(1,069)	669	(20)	(348)
Change in fair value of notes payable	-	-	-	-	(66)	167
Foreign Exchange Transaction (Gain) Loss	(13)	-	24	13	16	9
Other income (expenses) incl. Transaction Costs	-	738	7,604	-	848	(180)
Adjusted EBITDA	(3,335)	(1,853)	(3,885)	(2,659)	(1,857)	(2,038)

EXCEPTIONAL TEAM WITH PROVEN TRACK RECORD





Peter M. Carlson Chief Executive Officer

30 yrs+ of Finance and Operations experience in Fortune 50 and healthcare corporations, such as MiMedx, Metlife, and Wachovia.



Vincent Capone Chief Financial Officer & General Counsel 25 yrs+ of tech company experience KPMG, Morgan Lewis and Reed Smith LLP.



Jeremiah Sparks Chief Commercialization Officer 20 yrs+ of medical device marketing experience evidenced by positions held with Avita Medical and Allergan.



Stan Micek Interim Chief Operations Officer 20 yrs+ of product development and str

20 yrs+ of product development and strategic alliances, such as MiMedx and Aster Insights.



Kevin Plant VP of Research & Development

10 yrs+ of software and data science leadership experience at St. Jude and Abbott.



Louis Percoco General Manager – Manufacturing 30 yrs+ of experience in R&D and Production teams in Cardiology, Orthopedic, and Spine disciplines.



Mary Regan, PhD VP of Clinical Affairs

30 yrs+ years of clinical experience, with board positions held on the American Association of Wound Care Specialists and NWHS.



Christine Marks VP of Marketing & Commercialization

20 yrs+ of marketing experience for wound care medical device companies, such as BSN Medical and Lohmann & Raucher.




Prof. Paul Chadwick EVP of UK and EMEA Podiatrist with 15 yrs+ of experience in wound care and foot health. Most recently former CEO of Royal College of Podiatry in UK.

BOARD



Board of Directors



physicians.



Expert clinical guidance

The technology provides us with
high quality photos and gives us
a binary output in terms of
whether we need to surgically
remove an area of burned skin
or whether it will heal.

ßß

DeepView will significantly
transform how we treat DFUs
through continuous monitoring
and measurement ensuring an
accelerated healing trajectory
and prevent DFU reoccurrence.



CHRIS LEWIS

Consultant Burn Surgeon

Mr. Christopher Lewis is a Consultant Burn, Laser and Reconstructive Surgeon at the Northern Regional Burn Centre based at Newcastle's Royal Victoria Infirmary, with a special interest in emergency burn care, reconstruction and laser treatment.



PROF. PAUL CHADWICK

EVP of UK and EMEA Former CEO of the Royal College of Podiatry UK

Prof. Chadwick is a world-renowned clinical research scientist, wound care key opinion leader (KOL), and has an extensive publication record on diabetic wound management.

©2024 Spectral AI

REFERENCE LIST

- 1. Data from Spectral MD's IRB approved Proof of Concept Clinical Study
- 2. <u>https://www.cnn.com/2023/08/09/weather/maui-county-wildfires-hurricane-dora/index.html</u>
- 3. Pixel data per Spectral MD clinical studies.
- 4. Data from Spectral MD's IRB approved Proof of Concept Clinical Study
- 5. Clinicians are 50% accurate in assessing healing potential of DFUs https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7950518/
- Anyanwu JA, Cindass R. Burn Debridement, Grafting, and Reconstruction. [Updated 2023 May 29]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: <u>https://www.ncbi.nlm.nih.gov/books/NBK551717/</u>
- Assessment of burn depth and burn wound healing potential. Burns. Volume 34-6. September 2008, pages 761-769
- Huson HB, Phelan HA, G'Sell DJ, Smith S, Carter JE. If Seeing Was Believing A Retrospective Analysis of Potential Reduced Treatment Delays with a Novel Burn Wound Assessment Device. JBCR 2021;(42)S117-18
- 9. Definitive Healthcare 2019 Private Pay and CMS pay of inpatient versus outpatient DRG codes
- 10. The Effectiveness of Regionalized Burn Care: An Analysis of 6,873 Burn Admissions in North Carolina from 2000 to 2007.Regional Air Transport of Burn Patients: A Case for Telemedicine?

- Warriner R, Snyder RJ, Cardinal MH et al (2011) Differentiating diabetic foot ulcers that are unlikely to heal by 12 weeks following achieving 50% percent area reduction at 4 weeks. Int Wound J 8(6):632–7. <u>https://doi.org/10.1111/j.1742-481x.2011.00860.x</u>
- Sheenan P, Jones P et al (2003) Percent change in wound area of diabetic foot ulcers over a 4-week period is a robust predictor of complete healing in a 12-week prospective trial. Diabetes Care 26(6):1879–82 <u>https://doi.org/10.2337/diacare.26.6.1879</u>
- Carter NH, Leonard C, Rae L. Assessment of Outreach by a Regional Burn Center: Could Referral Criteria Revision Help with Utilization of Resources? JBCRi2018;39(2):245-51
- 14. Definitive Healthcare 2019 Cost and Claims Data from Medicare and Private Payer Estimates
- 15. American Medical Association Common Procedural Terminology CPT®
- Huson HB, Phelan HA, G'Sell DJ, Smith S, Carter JE. If Seeing Was Believing A Retrospective Analysis of Potential Reduced Treatment Delays with a Novel Burn Wound Assessment Device. JBCR 2021;(42)S117-18.
- 17. TAM and CAGR Global Burn Care Market Size & Share Report, 2021-2028
- TAM and CAGR Fortune Business Insights: Diabetic Foot Ulcer Treatment Market Worth \$11.16 Billion at 6.8% CAGR; Rise in Clinical Trials to Augment Market



FORWARD LOOKING STATEMENTS



Except for the historical information contained herein, this document contains forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding (i) our strategy, plans, objectives and initiatives, including but not limited to our plans and projected timelines to begin commercialization and product sales, launch new products, complete clinical trials, add additional clinical indications, (ii) the ability to be listed on the Nasdaq Global Market, (iii) Spectral Al's managements' expectations, (iv) potential government contracts, (v) expected beneficial outcomes and synergies, (vi) potential financing opportunities, (vii) Spectral Al's regulatory pathway for and timing of FDA, CE and UKCA regulatory submissions and approvals, (viii) Spectral Al's U.S. government contracts and future awards, (ix) the total anticipated target markets for burn wound and diabetic foot ulcers, (x) possible competitors, (xi) potential future indications and applications for DeepView and areas of interest supported by BARDA, (xii) Spectral Al's future and pending U.S. patent applications and foreign and international patent applications, and (xiii) pro forma information and other estimated values. The foregoing list of risk factors is not exhaustive. Management believes that these forward-looking statements are reasonable as and when made. However, such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those projected in the forward-looking statements. These risks and uncertainties include but are not limited to our ability to obtain and maintain necessary regulatory approvals, general economic conditions, consumer demand for our products and services, challenges relating to entering into and growing new business lines, the competitive environment, and the risk factors listed from time to time in our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, the Registration Statement on Form S-1, as amended, filed with the SEC on April 10, 2024 and any other SEC filings including the sections entitled "Cautionary Note Regarding Forward-Looking Statements", "Cautionary Note Regarding Forward-Looking Statements and Risk Factor Summary", "Risk Factors", "Management's Discussions and Analysis of Financial Condition and Results of Operations" and "Business" and in the Financial Statements. The Company undertakes no obligation to update forward-looking statements except as required by applicable securities laws. Readers are cautioned that forward-looking statements are not guarantees of future performance and are cautioned not to place undue reliance on any forward-looking statements.

Any financial projections in this presentation are forward-looking statements that are based on assumptions that are inherently subject to significant uncertainties and contingencies, many of which are beyond Spectral AI's control. While all projections are necessarily speculative, Spectral AI believes that the preparation of prospective financial information involves increasingly higher levels of uncertainty the further out the projection extends from the date of preparation. The assumptions and estimates underlying the projected results are inherently uncertain and are subject to a wide variety of significant business, economic and competitive risks and uncertainties that could cause actual results to differ materially from those contained in the projections. The inclusion of projections in this communication should not be regarded as an indication that Spectral AI, or its representatives, considered or consider the projections to be a reliable prediction of future events. Annualized, pro forma, projected and estimated numbers are used for illustrative purpose only, are not forecasts and may not reflect actual results.





Additional Information and Where to Find It

This presentation is provided for informational purposes only. Spectral AI investors and stockholders will be able to obtain copies of any documents filed with the SEC, without charge, at the SEC's website at www.sec.gov.

No Offer or Solicitation

This presentation and the information contained herein do not constitute (i) (a) a solicitation of a proxy, consent or authorization with respect to any securities or (b) an offer to sell or the solicitation of an offer to buy any security, commodity or instrument or related derivative, nor shall there be any sale of securities in any jurisdiction in which the offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction or (ii) an offer or commitment to lend, syndicate or arrange a financing, underwrite or purchase or act as an agent or advisor or in any other capacity with respect to any transaction, or commit capital, or to participate in any trading strategies. No offer of securities in the United States or to or for the account or benefit of U.S. persons (as defined in Regulation S under the U.S. Securities Act) shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act, or an exemption therefrom. Investors should consult with their counsel as to the applicable requirements for a purchaser to avail itself of any exemption under the Securities Act.

Trademarks

All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this presentation are for identification purposes only. Use of these names, trademarks and brands does not imply endorsement.



Connect with us

⊕ spectral-ai.com☑ ir@spectral-ai.com

■ Deep View SnapShot™ 30

